Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bahamas STEM News.
Press releases published on July 28, 2025
DataPelago Appoints John “JG” Chirapurath as President to Accelerate Growth in Data and AI
MOUNTAIN VIEW, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- DataPelago, the company behind the world’s first universal data processing engine for accelerated computing, today announced that tech industry veteran John “JG” Chirapurath has joined the company as …
NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference
CALABASAS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced that management …
Aeries Technology, Inc. (NASDAQ: AERT) Partners with Skydda.ai to Bring AI-Enabled SOC Operations to GCC Clients
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (NASDAQ: AERT), a global leader in AI-enabled value creation, business transformation, and Global Capability Center (GCC) delivery for private equity portfolio companies, has announced a …
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
OCALA, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) …
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
– Webinar to be held on Tuesday, July 29, 2025, at 1:00 p.m. ET – SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, …
Overwatch Imaging Secures $6M in Venture Funding
HOOD RIVER, Ore., July 28, 2025 (GLOBE NEWSWIRE) -- Overwatch Imaging, a leader in airborne imaging systems and intelligence automation software, has raised a new round of $6 million in venture capital financing to accelerate the go-to-market and partner- …
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective …
Aclaris Therapeutics Announces Leadership Transition
- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28, 2025 …
Telos Corporation, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening New Locations
ASHBURN, Va., July 28, 2025 (GLOBE NEWSWIRE) -- Telos Corporation (NASDAQ: TLS), an authorized enrollment provider, continues to expand locations to enroll consumers in the TSA PreCheck® program by opening 10 new TSA PreCheck enrollment locations in …
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its Phase II stage of its randomized, …
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act …
DatChat Granted Canadian Patent for Advanced Digital Privacy Technology
NEW BRUNSWICK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- DatChat, Inc. (Nasdaq: DATS) (“DatChat” or the “Company”), a secure messaging and social media company, today announced that the Canadian Patent Office has granted Canadian Patent No. 3,149,004, titled …
Maris-Tech Secures a $144,000 Order from a Customer in the Defense Industry for the Design and Development of Ruggedized AI Platform
The Company will Develop a New Product to Enable Advanced Tactical Video and Edge Computing Capabilities Rehovot, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in video and …
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025
Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration. Troculeucel was shown to internalize and digest amyloid …
IMUNON Announces Stock Dividend Boosting Shareholder Value
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 …
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel …
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25 SYDNEY, July 28, 2025 (GLOBE NEWSWIRE) -- Radiopharm …
Apyx Medical Corporation Announces Launch of Renuvion® in China
Strong clinical interest and early procedures completed Entered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance CLEARWATER, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Apyx Medical …
Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy
Increases total holdings to 1,535,772 HYPE Company to host investor webinar on Tuesday, July 29th at 2:00pm ET LAGUNA HILLS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced …